BioSpace News Archive

PharmaMar (PHM:MSE) today announced that its Phase II trial of lurbinectedin as a single agent for the treatment of relapsed small cell lung cancer (SCLC) has achieved its primary endpoint, by both investigator review and IRC (Independent Review Committee).

Visitors to Demo Widex ENERGY CELL™ Technology and Get a Live Hearing Demo of Second Generation Widex EVOKE™

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced the appointment of Natalie Holles, president and chief operating officer of Audentes Therapeutics, as a member of the company’s board of directors and Greg Whitehead as senior vice president and chief quality officer

Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced it is collaborating with St George’s University Hospital, London, and the European Molecular Genetics Quality Network (EMQN), based within the Manchester Centre for Genomic Medicine at Saint Mary’s Hospital, to develop reference material for non-invasive prenatal testing (NIPT).

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the appointment of Amit D. Munshi as Non-Executive Chairman of the Board of Directors.

Micronic released the new innovative 2.00ml Tubes with External thread. These 2.00ml tubes are the first tubes of its kind, enabling researchers to store high volume samples in a space-efficient 96-well format

Candor USA has announced that Max Howell joined Candor USA as Chief Product Officer to lead the direction and further development of Candor’s digital enterprise.

Nexus is pleased to announce that Gordon Breslav has been appointed Senior Vice President of Business Development for Nexus and its subsidiaries.

Physicians recognized for achievements in research, teaching, published works and leadership at SIR 2019 Annual Scientific Meeting

Neptune Wellness Solutions Inc., announced that it has received a judgment from the Superior Court of Québec regarding certain previously disclosed claims made by the Corporation’s former chief executive officer against the Corporation in respect of certain royalty payments alleged to be owed and owing to the Former CEO pursuant to the terms of an agreement entered into on February 23, 2001 between Neptune and a corporation controlled by the Former CEO.